Practical consequences of hepatitis C virus quasispecies for target-specific antivirals

Journal of Infectious Diseases

Volumn 198, Issue 6, 2008, Pages 797-799

  Fanning, Liam J ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CILUPREVIR; ITMN 191; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; EDITORIAL; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MONOTHERAPY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REPLICON; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS GENOME; VIRUS IMMUNITY; VIRUS MUTATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; MUTATION; SPECIES SPECIFICITY;

EID: 51749090448     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/591142     Document Type: Editorial

References (26)

1. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 2004; 85:3173-88.
2. Sakai A, Kaneko S, Honda M, Matsushita E, Kobayashi K. Quasispecies of hepatitis C virus in serum and in three different parts of the liver of patients with chronic hepatitis. Hepatology 1999; 30:556-61.
3. Domingo E. Quasispecies and the implications for virus persistence and escape. Clin Diagn Virol 1998; 10:97-101.
4. Wagner M, Lee J-H, Ruster B, et al. Dynamics of hepatitis C virus quasispecies turnover during interferon treatment. J Viral Hepat 2003; 10:413-22.
5. Farci P, Strazzera R, Alter HJ, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 2002; 99: 3081-6.
6. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339-44.
7. Dubuisson J, Helle F, Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol 2008; 10:821-7.
8. Casino C, McAllister J, Davidson F, et al. Variation of hepatitis C virus following serial transmission: multiple mechanisms of diversification of the hypervariable region and evidence for convergent genome evolution. J Gen Virol 1999; 80:717-25.
9. Evans DT, O'Connor DH, Jing P, et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med 1999; 5:1270-6.
10. Ray SC, Fanning L, Wang XH, Netski DM, Kenny-Walsh E, Thomas DL. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med 2005; 201:1753-9.
11. Carlson JM, Brumme ZL. HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective. Microbes Infect 2008; 10:455-61.
12. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-7.
13. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47:43-50.
14. Cubero M, Esteban JI, Otero T, et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008; 370:237-45.
15. Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 2005; 49:4305-14.
16. Lu L, Dekhtyar T, Masse S, et al. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antiviral Res 2007; 76:93-7.
17. Welsch C, Domingues FS, Susser S, et al. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol 2008; 9:R16.
18. Kennedy PT, Phillips N, Chandrasekhar J, Jacobs R, Jacobs M, Dusheiko G. Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping. Liver Int 2008; 28:699-704.
19. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68:1660-6.
20. Bartels DJ, Zhou Y, Zhang EZ. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3·4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198:800-7 (in this issue).
21. Zhou Y, Bartels DJ, Hanzelka BL, et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2008; 52:110-20.
22. Najera I, Richman DD, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1994; 10:1479-88.
23. Mullan B, Kenny-Walsh E, Collins JK, Shanahan F, Fanning LJ. Inferred hepatitis C virus quasispecies diversity is influenced by choice of DNA polymerase in reverse transcriptase-polymerase chain reactions. Anal Biochem 2001; 289:137-46.
24. Mullan B, Sheehy P, Shanahan F, Fanning L. Do Taq-generated RT-PCR products from RNA viruses accurately reflect viral genetic heterogeneity? J Viral Hepat 2004; 11:108-14.
25. Hoffmann C, Minkah N, Leipzig J, et al. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res 2007; 35:e91.
26. Ward CL, Dev A, Rigby S, et al. Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. J Viral Hepat 2008; 24 March (electronically published ahead of print).